Protective immunity against influenza H5N1 virus challenge in chickens by oral administration of recombinant Lactococcus lactis expressing neuraminidase

BMC Veterinary Research

Volumn 11, Issue 1, 2015, Pages

  Lei, Han ^a,b,c   Peng, Xiaojue ^c   Ouyang, Jiexiu ^c   Zhao, Daxian ^c   Jiao, Huifeng ^c   Shu, Handing ^c   Ge, Xinqi ^c  

^a SOUTHWEST JIAOTONG UNIVERSITY   (China)

^b State University of New York   (United States)

^c NANCHANG UNIVERSITY   (China)

Author keywords

H5N1 virus; L.lactis pNZ2103 NA; Protective immunity

Indexed keywords

INFLUENZA VACCINE; SIALIDASE;

ANIMAL; CHICKEN; GENETICS; GERMFREE ANIMAL; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INFLUENZA IN BIRDS; LACTOCOCCUS LACTIS; MASS IMMUNIZATION; METABOLISM; ORAL DRUG ADMINISTRATION; VIROLOGY;

ADMINISTRATION, ORAL; ANIMALS; CHICKENS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; LACTOCOCCUS LACTIS; MASS VACCINATION; NEURAMINIDASE; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 84926631472     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/s12917-015-0399-4     Document Type: Article

References (22)

1. Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol. 2007;7:267-78.
2. Pantin-Jackwood MJ, Suarez DL. Vaccination of domestic ducks against H5N1 HPAI: a review. Virus Res. 2013;178:21-34.
3. Cha RM, Smith D, Shepherd E, Davis CT, Donis R, Nguyen T. Suboptimal protection against H5N1 highly pathogenic avian influenza viruses from Vietnam in ducks vaccinated with commercial poultry vaccines. Vaccine. 2013;31:4953-60.
4. Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis. 2004;4:499-509.
5. Singh N, Pandey A, Mittal SK. Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Rev Mol Med. 2010;12:e14.
6. Horimoto T, Kawaoka Y. Designing vaccines for pandemic influenza. Curr Top Microbiol Immunol. 2009;333:165-76.
7. Easterbrook JD, Schwartzman LM, Gao J, Kash JC, Morens DM, Couzens L, et al. Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology. 2012;432:39-44.
8. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y, et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol. 2006;80:1959-64.
9. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol. 2008;6:349-62.
10. Lee JS, Shin KS, Pan JG, Kim CJ. Surface displayed viral antigens on salmonella carrier vaccine. Nat Biotechnol. 2000;18:645-8.
11. + T cells and antiviral protective immunity. J Virol. 2001;75:9665-70.
12. Van Huynegem K, Loos M, Steidler L. Immunomodulation by genetically engineered lactic acid bacteria. Front Biosci (Landmark Ed). 2009;14:4825-35.
13. Pontes DS, de Azevedo MS, Chatel JM, Langella P, Azevedo V, Miyoshi A. Lactococcus lactis as a live vector: heterologous protein production and DNA delivery systems. Protein Exp Purif. 2011;79:165-75.
14. Lei H, Xu Y, Chen J, Wei X, Lam DM. Immunoprotection against influenza H5N1 virus by oral administration of eneteric coated recombinant Lactococcus lactis mini-capsules. Virology. 2010;407:319-24.
15. Lei H, Sheng Z, Ding Q, Chen J, Wei X, Lam DM, et al. Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B. Clin Vaccine Immunol. 2011;18:1046-51.
16. Lei H, Peng X, Shu H, Zhao D. Intranasal immunization with live recombinant Lactococcus lactis combined with heat-labile toxin B subunit protects chickens from highly pathogenic avian influenza H5N1 virus. J Med Virol. 2014. doi: 10.1002/jmv.23983.
17. Wohlbold TJ, Krammer F. In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses. 2014;6:2465-94.
18. Rappuoli R, Dormitzer PR. Influenza: options to improve pandemic preparation. Science. 2012;336:1531-3.
19. Doyle TM, Hashem AM, Li C, Van Domselaar G, Larocque L, Wang J, et al. Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res. 2013;100:567-74.
20. Yuki Y, Kiyono H. New generation of mucosal adjuvant for the induction of protective immunity. Rev Med Virol. 2003;13:293-310.
21. Bermú dez-Humará n LG. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin. 2009;5:264-7.
22. Nicholson KG, Wod JM, Zamvon M. Influenza. Lancet. 2003;362:1733-45.